> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cadila Indian Drug Facility Cited After Inspection
- URL: https://www.fdaweb.com/cadila-indian-drug-facility-cited-after-inspection/
- Published: 2019-05-20T12:00:00.000Z
- Updated: 2026-09-15T01:27:50.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144139

An FDA inspection last month of Cadila Healthcare’s Gujarat, India manufacturing facility has led to a [23-page Form 483](https://www.fda.gov/media/125015/download?ref=fdaweb.com) that cites significant GMP violations. For example, the agency said the firm’s equipment and utensils were not cleaned and maintained at appropriate intervals to prevent contamination. The inspection also cited it for not establishing and following procedures designed to prevent microbiological contamination of drug products. And, aseptic processing areas were found to be deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.